These findings have been validated in other mouse models of AD, where young plasma treatments reduced the burden of amyloid plaques and phosphorylated tau, decreased the activation of microglia and astrocytes, and improved both object and spatial memory [57, 853, 854]. The gene discussed is MAPT; the disease is Alzheimer disease.